Novartis Receives EU Approval for Juvenile Arthritis Treatment - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Novartis Receives EU Approval for Juvenile Arthritis Treatment


Validation Week
SPOTLIGHT EVENT

IVT’s 19th Annual
Validation Week

October 22-24, 2013
San Diego, California

Brochure | Register

RELATED ARTICLES

More in GMPs/Validation

The European Commission (EC) has approved the use of Ilaris (canakinumab) in the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids, Novartis announced in a press release. SJIA is a rare and disabling form of childhood arthritis with limited treatment options. The condition is characterized by spiking fever, rash, and arthritis that can affect children as young as 2 years old and can continue into adulthood, the press release explained. Ilaris can be given as monotherapy or in combination with methotrexate.

Ilaris is a selective, fully human, monoclonal antibody that inhibits interleukin-1 (IL-1) beta, which is an important part of the body's immune system defenses. Excessive production of IL-1 beta plays a prominent role in certain inflammatory diseases. Ilaris neutralizes IL-1 beta for a sustained period of time, therefore inhibiting inflammation. Ilaris is approved for the treatment of SJIA in the US, for the symptomatic treatment of refractory acute gouty arthritis in the EU, and for treatment of cryopyrin-associated periodic syndromes (CAPS) in more than 60 countries.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here